Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor

Journal of Experimental Medicine

Volumn 213, Issue 10, 2016, Pages 1937-1950

  Tan, Eng M ^a   Smolen, Josef S ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR; ANTIBODY; ANTIGEN ANTIBODY COMPLEX;

ANTIGEN ANTIBODY COMPLEX; CLINICAL TRIAL (TOPIC); COMPLEMENT ACTIVATION; HUMAN; INFECTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; ANIMAL; ARTHRITIS, RHEUMATOID; BIOLOGICAL MODEL; IMMUNOLOGY; INFLAMMATION; METABOLISM;

ANIMALS; ANTIBODIES; ANTIGEN-ANTIBODY COMPLEX; ARTHRITIS, RHEUMATOID; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; RHEUMATOID FACTOR;

EID: 84992197087     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20160792     Document Type: Review

References (128)

1. Abdel Fattah, N.S., H.E. Hassan, Z.A. Galal, and S.E. El Okda. 2009. Assessment of anti-cyclic citrullinated peptide in psoriatic arthritis. BMC Res. Notes. 2:44. http://dx.doi.org/10.1186/1756-0500-2-44
2. Abedi-Valugerdi, M., A. Ridderstad, S. al-Balaghi, and E. Möller. 1995. Human IgG rheumatoid factors and RF-like immune complexes induce IgG1 rheumatoid factor production in mice. Scand. J. Immunol. 41:575-582. http://dx.doi.org/10.1111/j.1365-3083.1995.tb03610.x
3. Abruzzo, J.L., and C.L. Christian. 1961. The induction of a rheumatoid factor-like substance in rabbits. J. Exp. Med. 114:791-806. http://dx.doi.org/10.1084/jem.114.5.791
4. Aho, K., M. Heliövaara, J. Maatela, T. Tuomi, and T. Palosuo. 1991. Rheumatoid factors antedating clinical rheumatoid arthritis. J. Rheumatol. 18:1282-1284
5. Aho, K., R. von Essen, P. Kurki, T. Palosuo, and M. Heliövaara. 1993. Antikeratin antibody and antiperinuclear factor as markers for subclinical rheumatoid disease process. J. Rheumatol. 20:1278-1281
6. Aitcheson, C.T., C. Peebles, F. Joslin, and E.M. Tan. 1980. Characteristics of antinuclear antibodies in rheumatoid arthritis. Reactivity of rheumatoid factor with a histone-dependent nuclear antigen. Arthritis Rheum. 23:528-538. http://dx.doi.org/10.1002/art.1780230503
7. Aletaha, D., F. Alasti, and J.S. Smolen. 2013. Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity. Ann. Rheum. Dis. 72:875-880. http://dx.doi.org/10.1136/annrheumdis-2012-201517
8. Aletaha, D., F. Alasti, and J.S. Smolen. 2015. Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials. Arthritis Res. Ther. 17:229. http://dx.doi.org/10.1186/s13075-015-0736-9
9. Alspaugh, M.A., and E.M. Tan. 1976. Serum antibody in rheumatoid arthritis reactive with a cell-associated antigen. Demonstration by precipitation and immunofluorescence. Arthritis Rheum. 19:711-719. http://dx.doi.org/10.1002/1529-0131(197607/08)19:4<711::AID-ART1780190409>3.0.CO;2-I
10. Alspaugh, M.A., N. Talal, and E.M. Tan. 1976. Differentiation and characterization of autoantibodies and their antigens in Sjögren's syndrome. Arthritis Rheum. 19:216-222. http://dx.doi.org/10.1002/art.1780190214
11. Alspaugh, M.A., F.C. Jensen, H. Rabin, and E.M. Tan. 1978. Lymphocytes transformed by Epstein-Barr virus. Induction of nuclear antigen reactive with antibody in rheumatoid arthritis. J. Exp. Med. 147:1018-1027. http://dx.doi.org/10.1084/jem.147.4.1018
12. Alspaugh, M.A., G. Henle, E.T. Lennette, and W. Henle. 1981. Elevated levels of antibodies to Epstein-Barr virus antigens in sera and synovial fluids of patients with rheumatoid arthritis. J. Clin. Invest. 67:1134-1140. http://dx.doi.org/10.1172/JCI110127
13. Aringer, M., and J.S. Smolen. 2012. Therapeutic blockade of TNF in patients with SLE-promising or crazy? Autoimmun. Rev. 11:321-325. http://dx.doi.org/10.1016/j.autrev.2011.05.001
14. Avila, M.D., E. Escolar, and G.A. Lamas. 2014. Chelation therapy after the trial to assess chelation therapy: results of a unique trial. Curr. Opin. Cardiol. 29:481-488. http://dx.doi.org/10.1097/HCO.0000000000000096
15. Bamonti, F., A. Fulgenzi, C. Novembrino, and M.E. Ferrero. 2011. Metal chelation therapy in rheumathoid arthritis: a case report. Successful management of rheumathoid arthritis by metal chelation therapy. Biometals. 24:1093-1098. http://dx.doi.org/10.1007/s10534-011-9467-9
16. Baron, D., and J.L. Strominger. 1978. Partial purification and properties of the Epstein-Barr virus-associated nuclear antigen. J. Biol. Chem. 253:2875-2881
17. Billings, P.B., S.O. Hoch, P.J. White, D.A. Carson, and J.H. Vaughan. 1983. Antibodies to the Epstein-Barr virus nuclear antigen and to rheumatoid arthritis nuclear antigen identify the same polypeptide. Proc. Natl. Acad. Sci. USA. 80:7104-7108. http://dx.doi.org/10.1073/pnas.80.23.7104
18. Binder, N.B., A. Puchner, B. Niederreiter, S. Hayer, H. Leiss, S. Blüml, R. Kreindl, J.S. Smolen, and K. Redlich. 2013. Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis. Arthritis Rheum. 65:608-617. http://dx.doi.org/10.1002/art.37797
19. Blaschke, S., G. Schwarz, D. Moneke, L. Binder, G. Müller, and M. Reuss-Borst. 2000. Epstein-Barr virus infection in peripheral blood mononuclear cells, synovial fluid cells, and synovial membranes of patients with rheumatoid arthritis. J. Rheumatol. 27:866-873
20. Bloch, K.J., W.W. Buchanan, M.J. Wohl, and J.J. Bunim. 1965. Sjögren's syndrome. A clinical, pathological, and serological study of sixty-two cases. Medicine (Baltimore). 44:187-231. http://dx.doi.org/10.1097/00005792-196505000-00001
21. Böhler, C., H. Radner, J.S. Smolen, and D. Aletaha. 2013. Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis. Ann. Rheum. Dis. 72:241-244. http://dx.doi.org/10.1136/annrheumdis-2012-202297
22. Born, T., C.N. Kontoghiorghe, A. Spyrou, A. Kolnagou, and G.J. Kontoghiorghes. 2013. EDTA chelation reappraisal following new clinical trials and regular use in millions of patients: review of preliminary findings and risk/benefit assessment. Toxicol. Mech. Methods. 23:11-17. http://dx.doi.org/10.3109/15376516.2012.730562
23. Catalano, M.A., D.A. Carson, S.F. Slovin, D.D. Richman, and J.H. Vaughan. 1979. Antibodies to Epstein-Barr virus-determined antigens in normal subjects and in patients with seropositive rheumatoid arthritis. Proc. Natl. Acad. Sci. USA. 76:5825-5828. http://dx.doi.org/10.1073/pnas.76.11.5825
24. Catalano, M.A., D.A. Carson, J.C. Niederman, P. Feorino, and J.H. Vaughan. 1980. Antibody to the rheumatoid arthritis nuclear antigen. Its relationship to in vivo Epstein-Barr virus infection. J. Clin. Invest. 65:1238-1242. http://dx.doi.org/10.1172/JCI109779
25. Chang, K.L., Y.Y. Chen, D. Shibata, and L.M. Weiss. 1992. Description of an in situ hybridization methodology for detection of Epstein-Barr virus RNA in paraffin-embedded tissues, with a survey of normal and neoplastic tissues. Diagn. Mol. Pathol. 1:246-255. http://dx.doi.org/10.1097/00019606-199203000-00037
26. Chang, X., R. Yamada, A. Suzuki, Y. Kochi, T. Sawada, and K. Yamamoto. 2005. Citrullination of fibronectin in rheumatoid arthritis synovial tissue. Rheumatology (Oxford). 44:1374-1382. http://dx.doi.org/10.1093/rheumatology/kei023
27. Chiu, W.C., C.M. Chen, T.T. Cheng, H.L. You, S.F. Yu, L.H. Weng, H.Y. Huang, C.C. Huang, and C.J. Chen. 2013. EBV-encoded small RNA1 and nonresolving inflammation in rheumatoid arthritis. Kaohsiung J. Med. Sci. 29:606-610. http://dx.doi.org/10.1016/j.kjms.2013.04.002
28. Clarke, C.N., N.E. Clarke, and R.E. Mosher. 1956. Treatment of angina pectoris with disodium ethylene diamine tetraacetic acid. Am. J. Med. Sci. 232:654-666. http://dx.doi.org/10.1097/00000441-195612000-00006
29. Cush, J.J., J.B. Splawski, R. Thomas, J.E. McFarlin, H. Schulze-Koops, L.S. Davis, K. Fujita, and P.E. Lipsky. 1995. Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthritis Rheum. 38:96-104. http://dx.doi.org/10.1002/art.1780380115
30. Debets, J.M., C.J. Van der Linden, I.E. Dieteren, J.F. Leeuwenberg, and W.A. Buurman. 1988. Fc-receptor cross-linking induces rapid secretion of tumor necrosis factor (cachectin) by human peripheral blood monocytes. J. Immunol. 141:1197-1201
31. de Hair, M.J., M.G. van de Sande, T.H. Ramwadhdoebe, M. Hansson, R. Landewé, C. van der Leij, M. Maas, G. Serre, D. van Schaardenburg, L. Klareskog, et al. 2014. Features of the synovium of individuals at risk of developing rheumatoid arthritis: implications for understanding preclinical rheumatoid arthritis. Arthritis Rheumatol. 66:513-522. http://dx.doi.org/10.1002/art.38273
32. De Rycke, L., A.P. Nicholas, T. Cantaert, E. Kruithof, J.D. Echols, B. Vandekerckhove, E.M. Veys, F. De Keyser, and D. Baeten. 2005. Synovial intracellular citrullinated proteins colocalizing with peptidyl arginine deiminase as pathophysiologically relevant antigenic determinants of rheumatoid arthritis-specific humoral autoimmunity. Arthritis Rheum. 52:2323-2330. http://dx.doi.org/10.1002/art.21220
33. Dmytrijuk, A., K. Robie-Suh, M.H. Cohen, D. Rieves, K. Weiss, and R. Pazdur. 2008. FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist. 13:993-1000. http://dx.doi.org/10.1634/theoncologist.2008-0086
34. Edelman, G.M., H.G. Kunkel, and E.C. Franklin. 1958. Interaction of the rheumatoid factor with antigen-antibody complexes and aggregated gamma globulin. J. Exp. Med. 108:105-120. http://dx.doi.org/10.1084/jem.108.1.105
35. Fan, H., and M.L. Gulley. 2001. Molecular methods for detecting Epstein-Barr virus (Part I): In situ hybridization to Epstein-Barr virus-encoded RNA (EBER) transcripts. Methods Mol. Med. 49:301-311
36. Fehr, T., M.F. Bachmann, E. Bucher, U. Kalinke, F.E. Di Padova, A.B. Lang, H. Hengartner, and R.M. Zinkernagel. 1997. Role of repetitive antigen patterns for induction of antibodies against antibodies. J. Exp. Med. 185:1785-1792. http://dx.doi.org/10.1084/jem.185.10.1785
37. Feldmann, M., and R.N. Maini. 2003. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat. Med. 9:1245-1250. http://dx.doi.org/10.1038/nm939
38. Ferrell, P.B., C.T. Aitcheson, G.R. Pearson, and E.M. Tan. 1981. Seroepidemiological study of relationships between Epstein-Barr virus and rheumatoid arthritis. J. Clin. Invest. 67:681-687. http://dx.doi.org/10.1172/JCI110083
39. Franklin, E.C., H.R. Holman, H.J. Muller-Eberhard, and H.G. Kunkel. 1957. An unusual protein component of high molecular weight in the serum of certain patients with rheumatoid arthritis. J. Exp. Med. 105:425-438. http://dx.doi.org/10.1084/jem.105.5.425
40. Fritsch, R., D. Eselböck, K. Skriner, B. Jahn-Schmid, C. Scheinecker, B. Bohle, M. Tohidast-Akrad, S. Hayer, J. Neumüller, S. Pinol-Roma, et al. 2002. Characterization of autoreactive T cells to the autoantigens heterogeneous nuclear ribonucleoprotein A2 (RA33) and filaggrin in patients with rheumatoid arthritis. J. Immunol. 169:1068-1076. http://dx.doi.org/10.4049/jimmunol.169.2.1068
41. Hardy, R.R. 2006. B-1 B cells: development, selection, natural autoantibody and leukemia. Curr. Opin. Immunol. 18:547-555. http://dx.doi.org/10.1016/j.coi.2006.07.010
42. Hardy, R.R., K. Hayakawa, M. Shimizu, K. Yamasaki, and T. Kishimoto. 1987. Rheumatoid factor secretion from human Leu-1+ B cells. Science. 236:81-83. http://dx.doi.org/10.1126/science.3105057
43. Hartlage, A.S., T. Liu, J.T. Patton, S.L. Garman, X. Zhang, H. Kurt, G. Lozanski, M.E. Lustberg, M.A. Caligiuri, and R.A. Baiocchi. 2015. The Epstein-Barr virus lytic protein BZLF1 as a candidate target antigen for vaccine development. Cancer Immunol. Res. 3:787-794. http://dx.doi.org/10.1158/2326-6066.CIR-14-0242
44. Hennessy, K., and E. Kieff. 1983. One of two Epstein-Barr virus nuclear antigens contains a glycine-alanine copolymer domain. Proc. Natl. Acad. Sci. USA. 80:5665-5669. http://dx.doi.org/10.1073/pnas.80.18.5665
45. Holers, V.M. 2003. The complement system as a therapeutic target in autoimmunity. Clin. Immunol. 107:140-151. http://dx.doi.org/10.1016/S1521-6616(03)00034-2
46. Hollingsworth, J.W., E.R. Siegel, and W.A. Creasey. 1967. Granulocyte survival in synovial exudate of patients with rheumatoid arthritis and other inflammatory joint diseases. Yale J. Biol. Med. 39:289-296
47. Holmdahl, R., C. Nordling, K. Rubin, A. Tarkowski, and L. Klareskog. 1986. Generation of monoclonal rheumatoid factors after immunization with collagen II-anti-collagen II immune complexes. An anti-idiotypic antibody to anti-collagen II is also a rheumatoid factor. Scand. J. Immunol. 24:197-203. http://dx.doi.org/10.1111/j.1365-3083.1986.tb02086.x
48. Iwakiri, D. 2014. Epstein-Barr virus-encoded RNAs: Key molecules in viral pathogenesis. Cancers (Basel). 6:1615-1630. http://dx.doi.org/10.3390/cancers6031615
49. Iwakiri, D., and K. Takada. 2010. Role of EBERs in the pathogenesis of EBV infection. Adv. Cancer Res. 107:119-136. http://dx.doi.org/10.1016/S0065-230X(10)07004-1
50. Jose, P.J., I.K. Moss, R.N. Maini, and T.J. Williams. 1990. Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase. Ann. Rheum. Dis. 49:747-752. http://dx.doi.org/10.1136/ard.49.10.747
51. Kalli, K.R., P. Hsu, and D.T. Fearon. 1994. Therapeutic uses of recombinant complement protein inhibitors. Springer Semin. Immunopathol. 15:417-431. http://dx.doi.org/10.1007/BF01837368
52. Kinloch, A., V. Tatzer, R. Wait, D. Peston, K. Lundberg, P. Donatien, D. Moyes, P.C. Taylor, and P.J. Venables. 2005. Identification of citrullinated a-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res. Ther. 7:R1421-R1429. http://dx.doi.org/10.1186/ar1845
53. Kinloch, A., K. Lundberg, R. Wait, N. Wegner, N.H. Lim, A.J. Zendman, T. Saxne, V. Malmström, and P.J. Venables. 2008. Synovial fluid is a site of citrullination of autoantigens in inflammatory arthritis. Arthritis Rheum. 58:2287-2295. http://dx.doi.org/10.1002/art.23618
54. Klareskog, L., K. Lundberg, and V. Malmström. 2013. Autoimmunity in rheumatoid arthritis: citrulline immunity and beyond. Adv. Immunol. 118:129-158. http://dx.doi.org/10.1016/B978-0-12-407708-9.00003-0
55. Koide, J., K. Takada, M. Sugiura, H. Sekine, T. Ito, K. Saito, S. Mori, T. Takeuchi, S. Uchida, and T. Abe. 1997. Spontaneous establishment of an Epstein-Barr virus-infected fibroblast line from the synovial tissue of a rheumatoid arthritis patient. J. Virol. 71:2478-2481
56. Lam, J., S. Takeshita, J.E. Barker, O. Kanagawa, F.P. Ross, and S.L. Teitelbaum. 2000. TNF-a induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106:1481-1488. http://dx.doi.org/10.1172/JCI11176
57. Lamas, G.A., C. Goertz, R. Boineau, D.B. Mark, T. Rozema, R.L. Nahin, L. Lindblad, E.F. Lewis, J. Drisko, and K.L. Lee. TACT Investigators. 2013. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA. 309:1241-1250. http://dx.doi.org/10.1001/jama.2013.2107
58. Leipzig, L.J., A.J. Boyle, and D.S. McCann. 1970. Case histories of rheumatoid arthritis treated with sodium or magnesium EDTA. J. Chronic Dis. 22:553-563. http://dx.doi.org/10.1016/0021-9681(70)90032-9
59. Lima, I., and M. Santiago. 2010. Antibodies against cyclic citrullinated peptides in infectious diseases-a systematic review. Clin. Rheumatol. 29:1345-1351. http://dx.doi.org/10.1007/s10067-010-1544-x
60. Magnusson, M., M. Brisslert, K. Zendjanchi, M. Lindh, and M.I. Bokarewa. 2010. Epstein-Barr virus in bone marrow of rheumatoid arthritis patients predicts response to rituximab treatment. Rheumatology (Oxford). 49:1911-1919. http://dx.doi.org/10.1093/rheumatology/keq159
61. Maini, R.N., F.C. Breedveld, J.R. Kalden, J.S. Smolen, D. Davis, J.D. Macfarlane, C. Antoni, B. Leeb, M.J. Elliott, J.N. Woody, et al. 1998. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41:1552-1563. http://dx.doi.org/10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W
62. Mannik, M. 1992. Rheumatoid factors in the pathogenesis of rheumatoid arthritis. J. Rheumatol. Suppl. 32:46-49
63. Masson-Bessière, C., M. Sebbag, E. Girbal-Neuhauser, L. Nogueira, C. Vincent, T. Senshu, and G. Serre. 2001. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the a-and β-chains of fibrin. J. Immunol. 166:4177-4184. http://dx.doi.org/10.4049/jimmunol.166.6.4177
64. Mathsson, L., J. Lampa, M. Mullazehi, and J. Rönnelid. 2006. Immune complexes from rheumatoid arthritis synovial fluid induce FcgammaRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-a by peripheral blood mononuclear cells. Arthritis Res. Ther. 8:R64. http://dx.doi.org/10.1186/ar1926
65. Mehraein, Y., C. Lennerz, S. Ehlhardt, K. Remberger, A. Ojak, and K.D. Zang. 2004. Latent Epstein-Barr virus (EBV) infection and cytomegalovirus (CMV) infection in synovial tissue of autoimmune chronic arthritis determined by RNA-and DNA-in situ hybridization. Mod. Pathol. 17:781-789. http://dx.doi.org/10.1038/modpathol.3800119
66. Milgrom, F., O. Tönder, and U. Loza. 1964. Modification of the Waaler-Rose test using formalinized sheep erythrocytes. Arthritis Rheum. 7:1-7. http://dx.doi.org/10.1002/art.1780070102
67. Moxley, G., and S. Ruddy. 1985. Elevated C3 anaphylatoxin levels in synovial fluids from patients with rheumatoid arthritis. Arthritis Rheum. 28:1089-1095. http://dx.doi.org/10.1002/art.1780281003
68. Nathan, C., and A. Ding. 2010. Nonresolving inflammation. Cell. 140:871-882. http://dx.doi.org/10.1016/j.cell.2010.02.029
69. Natvig, J.B., I. Randen, K. Thompson, O. Førre, R.A. Mageed, R. Jefferis, D.A. Carson, H. Tighe, V. Pascual, K.D. Victor, et al. 1990. Probing of the rheumatoid factor (RF) V gene repertoire in rheumatoid arthritis (RA) by hybridoma clones. Clin. Exp. Rheumatol. 8:75-80
70. Newkirk, M.M. 2002. Rheumatoid factors: what do they tell us? J. Rheumatol. 29:2034-2040
71. Newkirk, M.M., K.N. Watanabe Duffy, J. Leclerc, N. Lambert, and J.B. Shiroky. 1994. Detection of cytomegalovirus, Epstein-Barr virus and herpes virus-6 in patients with rheumatoid arthritis with or without Sjögren's syndrome. Br. J. Rheumatol. 33:317-322. http://dx.doi.org/10.1093/rheumatology/33.4.317
72. Ng, K.C., K.A. Brown, J.D. Perry, and E.J. Holborow. 1980. Anti-RANA antibody: a marker for seronegative and seropositive rheumatoid arthritis. Lancet. 315:447-449. http://dx.doi.org/10.1016/S0140-6736(80)90997-6
73. Nielen, M.M., D. van Schaardenburg, H.W. Reesink, R.J. van de Stadt, I.E. van der Horst-Bruinsma, M.H. de Koning, M.R. Habibuw, J.P. Vandenbroucke, and B.A. Dijkmans. 2004. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 50:380-386. http://dx.doi.org/10.1002/art.20018
74. Nienhuis, R.L., and E. Mandema. 1964. A new serum factor in patients with rheumatoid arthritis; the antiperinuclear factor. Ann. Rheum. Dis. 23:302-305. http://dx.doi.org/10.1136/ard.23.4.302
75. Norberg, B., A. Bjelle, and S. Eriksson. 1983. Joint fluid leukocytosis of patients with rheumatoid arthritis evidence for neutrophil and monocyte chemotaxis in vivo. Clin. Rheumatol. 2:237-242. http://dx.doi.org/10.1007/BF02041397
76. Okroj, M., D. Heinegård, R. Holmdahl, and A.M. Blom. 2007. Rheumatoid arthritis and the complement system. Ann. Med. 39:517-530. http://dx.doi.org/10.1080/07853890701477546
77. Paimela, L., M. Gripenberg, P. Kurki, and M. Leirisalo-Repo. 1992. Antikeratin antibodies: diagnostic and prognostic markers for early rheumatoid arthritis. Ann. Rheum. Dis. 51:743-746. http://dx.doi.org/10.1136/ard.51.6.743
78. Peguero, J.G., I. Arenas, and G.A. Lamas. 2014. Chelation therapy and cardiovascular disease: connecting scientific silos to benefit cardiac patients. Trends Cardiovasc. Med. 24:232-240. http://dx.doi.org/10.1016/j.tcm.2014.06.002
79. Plotz, C.M., and J.M. Singer. 1956. The latex fixation test. I. Application to the serologic diagnosis of rheumatoid arthritis. Am. J. Med. 21:888-892
80. Rantapää-Dahlqvist, S., B.A. de Jong, E. Berglin, G. Hallmans, G. Wadell, H. Stenlund, U. Sundin, and W.J. van Venrooij. 2003. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 48:2741-2749. http://dx.doi.org/10.1002/art.11223
81. Reyes, P.A., J.G. Maluf, J.G. Curd, and J.H. Vaughan. 1983. Association of rheumatoid factor with complement activation in rheumatoid arthritis and other diseases. Clin. Exp. Immunol. 53:391-396
82. Rhodes, G., D.A. Carson, J. Valbracht, R. Houghten, and J.H. Vaughan. 1985. Human immune responses to synthetic peptides from the Epstein-Barr nuclear antigen. J. Immunol. 134:211-216
83. Robitaille, P., N.J. Zvaifler, and E.M. Tan. 1973. Antinuclear antibodies and nuclear antigens in rheumatoid synovial fluids. Clin. Immunol. Immunopathol. 1:385-397. http://dx.doi.org/10.1016/0090-1229(73)90055-X
84. Romero, V., J. Fert-Bober, P.A. Nigrovic, E. Darrah, U.J. Haque, D.M. Lee, J. van Eyk, A. Rosen, and F. Andrade. 2013. Immune-mediated poreforming pathways induce cellular hypercitrullination and generate citrullinated autoantigens in rheumatoid arthritis. Sci. Transl. Med. 5:209ra150. http://dx.doi.org/10.1126/scitranslmed.3006869
85. Rose, H.M., C. Ragan, E. Pearce, and M.O. Lipman. 1948. Differential agglutination of normal and sensitized sheep erythrocytes by sera of patients with rheumatoid arthritis. Proc. Soc. Exp. Biol. Med. 68:1-6. http://dx.doi.org/10.3181/00379727-68-16375
86. Saal, J.G., M. Krimmel, M. Steidle, F. Gerneth, S. Wagner, P. Fritz, S. Koch, J. Zacher, S. Sell, H. Einsele, and C.A. Müller. 1999. Synovial Epstein-Barr virus infection increases the risk of rheumatoid arthritis in individuals with the shared HLA-DR4 epitope. Arthritis Rheum. 42:1485-1496. http://dx.doi.org/10.1002/1529-0131(199907)42:7<1485::AID-ANR24>3.0.CO;2-7
87. Sabharwal, U.K., J.H. Vaughan, S. Fong, P.H. Bennett, D.A. Carson, and J.G. Curd. 1982. Activation of the classical pathway of complement by rheumatoid factors. Assessment by radioimmunoassay for C4. Arthritis Rheum. 25:161-167. http://dx.doi.org/10.1002/art.1780250208
88. Saito, I., B. Servenius, T. Compton, and R.I. Fox. 1989. Detection of Epstein-Barr virus DNA by polymerase chain reaction in blood and tissue biopsies from patients with Sjogren's syndrome. J. Exp. Med. 169:2191-2198. http://dx.doi.org/10.1084/jem.169.6.2191
89. Schellekens, G.A., B.A. de Jong, F.H. van den Hoogen, L.B. van de Putte, and W.J. van Venrooij. 1998. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J. Clin. Invest. 101:273-281. http://dx.doi.org/10.1172/JCI1316
90. Schellekens, G.A., H. Visser, B.A. de Jong, F.H. van den Hoogen, J.M. Hazes, F.C. Breedveld, and W.J. van Venrooij. 2000. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 43:155-163. http://dx.doi.org/10.1002/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3
91. Scotet, E., J. David-Ameline, M.A. Peyrat, A. Moreau-Aubry, D. Pinczon, A. Lim, J. Even, G. Semana, J.M. Berthelot, R. Breathnach, et al. 1996. T cell response to Epstein-Barr virus transactivators in chronic rheumatoid arthritis. J. Exp. Med. 184:1791-1800. http://dx.doi.org/10.1084/jem.184.5.1791
92. Shi, J., R. Knevel, P. Suwannalai, M.P. van der Linden, G.M. Janssen, P.A. van Veelen, N.E. Levarht, A.H. van der Helm-van Mil, A. Cerami, T.W. Huizinga, et al. 2011. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc. Natl. Acad. Sci. USA. 108:17372-17377. http://dx.doi.org/10.1073/pnas.1114465108
93. Shi, J., L.A. van de Stadt, E.W. Levarht, T.W. Huizinga, D. Hamann, D. van Schaardenburg, R.E. Toes, and L.A. Trouw. 2014. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann. Rheum. Dis. 73:780-783. http://dx.doi.org/10.1136/annrheumdis-2013-204154
94. Sidhu, M.S., B.M. Saour, and W.E. Boden. 2014. A TACTful reappraisal of chelation therapy in cardiovascular disease. Nat. Rev. Cardiol. 11:180-183. http://dx.doi.org/10.1038/nrcardio.2013.176
95. Simon, M., E. Girbal, M. Sebbag, V. Gomès-Daudrix, C. Vincent, G. Salama, and G. Serre. 1993. The cytokeratin filament-aggregating protein filaggrin is the target of the so-called "antikeratin antibodies, "autoantibodies specific for rheumatoid arthritis. J. Clin. Invest. 92:1387-1393. http://dx.doi.org/10.1172/JCI116713
96. Singh, U., S. Singh, N.K. Singh, P.K. Verma, and S. Singh. 2011. Anticyclic citrullinated peptide autoantibodies in systemic lupus erythematosus. Rheumatol. Int. 31:765-767. http://dx.doi.org/10.1007/s00296-010-1374-9
97. Sjöholm, A.G., K. Berglund, U. Johnson, A.B. Laurell, and G. Sturfelt. 1986. C1 activation, with C1q in excess of functional C1 in synovial fluid from patients with rheumatoid arthritis. Int. Arch. Allergy Appl. Immunol. 79:113-119. http://dx.doi.org/10.1159/000233956
98. Smolen, J.S., D. Aletaha, and G. Steiner. 2009. Does damage cause inflammation? Revisiting the link between joint damage and inflammation. Ann. Rheum. Dis. 68:159-162. http://dx.doi.org/10.1136/ard.2008.099382
99. Smolen, J.S., P. Nash, P. Durez, S. Hall, E. Ilivanova, F. Irazoque-Palazuelos, P. Miranda, M.C. Park, K. Pavelka, R. Pedersen, et al. 2013. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRE SER VE): a randomised controlled trial. Lancet. 381:918-929. http://dx.doi.org/10.1016/S0140-6736(12)61811-X
100. Sokolove, J., D.S. Johnson, L.J. Lahey, C.A. Wagner, D. Cheng, G.M. Thiele, K. Michaud, H. Sayles, A.M. Reimold, L. Caplan, et al. 2014. Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis. Arthritis Rheumatol. 66:813-821. http://dx.doi.org/10.1002/art.38307
101. Takeda, T., Y. Mizugaki, L. Matsubara, S. Imai, T. Koike, and K. Takada. 2000. Lytic Epstein-Barr virus infection in the synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum. 43:1218-1225. http://dx.doi.org/10.1002/1529-0131(200006)43:6<1218::AID-ANR4>3.0.CO;2-2
102. Takei, M., K. Mitamura, S. Fujiwara, T. Horie, J. Ryu, S. Osaka, S. Yoshino, and S. Sawada. 1997. Detection of Epstein-Barr virus-encoded small RNA 1 and latent membrane protein 1 in synovial lining cells from rheumatoid arthritis patients. Int. Immunol. 9:739-743. http://dx.doi.org/10.1093/intimm/9.5.739
103. Tan, E.M. 1979. The possible role of Epstein-Barr virus in rheumatoid arthritis. Rev. Infect. Dis. 1:997-1006. http://dx.doi.org/10.1093/clinids/1.6.997
104. Tan, E.M. 1989. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv. Immunol. 44:93-151. http://dx.doi.org/10.1016/S0065-2776(08)60641-0
105. Tan, E.M., and J. Zhang. 2008. Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol. Rev. 222:328-340. http://dx.doi.org/10.1111/j.1600-065X.2008.00611.x
106. Tanimoto, K., N.R. Cooper, J.S. Johnson, and J.H. Vaughan. 1975. Complement fixation by rheumatoid factor. J. Clin. Invest. 55:437-445. http://dx.doi.org/10.1172/JCI107949
107. Tosato, G., A.D. Steinberg, R. Yarchoan, C.A. Heilman, S.E. Pike, V. De Seau, and R.M. Blaese. 1984. Abnormally elevated frequency of Epstein-Barr virus-infected B cells in the blood of patients with rheumatoid arthritis. J. Clin. Invest. 73:1789-1795. http://dx.doi.org/10.1172/JCI111388
108. Trouw, L.A., E.M. Haisma, E.W. Levarht, D. van der Woude, A. Ioan-Facsinay, M.R. Daha, T.W. Huizinga, and R.E. Toes. 2009. Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. Arthritis Rheum. 60:1923-1931. http://dx.doi.org/10.1002/art.24622
109. Uysal, H., R. Bockermann, K.S. Nandakumar, B. Sehnert, E. Bajtner, A. Engström, G. Serre, H. Burkhardt, M.M. Thunnissen, and R. Holmdahl. 2009. Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J. Exp. Med. 206:449-462. http://dx.doi.org/10.1084/jem.20081862
110. van Venrooij, W.J., and A.J. Zendman. 2008. Anti-CCP2 antibodies: an overview and perspective of the diagnostic abilities of this serological marker for early rheumatoid arthritis. Clin. Rev. Allergy Immunol. 34:36-39. http://dx.doi.org/10.1007/s12016-007-8029-y
111. Vaughan, J.H. 1956. Behavior of the rheumatoid arthritis agglutinating factor with immune precipitates. J. Immunol. 77:181-188
112. Venables, P. 1988. Epstein-Barr virus infection and autoimmunity in rheumatoid arthritis. Ann. Rheum. Dis. 47:265-269. http://dx.doi.org/10.1136/ard.47.4.265
113. Venables, P.J., T. Pawlowski, P.A. Mumford, C. Brown, D.H. Crawford, and R.N. Maini. 1988. Reaction of antibodies to rheumatoid arthritis nuclear antigen with a synthetic peptide corresponding to part of Epstein-Barr nuclear antigen 1. Ann. Rheum. Dis. 47:270-279. http://dx.doi.org/10.1136/ard.47.4.270
114. Vossenaar, E.R., N. Després, E. Lapointe, A. van der Heijden, M. Lora, T. Senshu, W.J. van Venrooij, and H.A. Ménard. 2004. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res. Ther. 6:R142-R150. http://dx.doi.org/10.1186/ar1149
115. Waaler, E. 1940. On the occurrence of a factor in human serum activating the specific agglutination of sheep blood corpuscles. Acta Pathologica, Microbiologica, et Immunologica Scandinavica. 17:172-188. http://dx.doi.org/10.1111/j.1699-0463.1940.tb01475.x
116. Wagner, E., and M.M. Frank. 2010. Therapeutic potential of complement modulation. Nat. Rev. Drug Discov. 9:43-56. http://dx.doi.org/10.1038/nrd3011
117. Wagner, H.J., G. Bein, A. Bitsch, and H. Kirchner. 1992. Detection and quantification of latently infected B lymphocytes in Epstein-Barr virus-seropositive, healthy individuals by polymerase chain reaction. J. Clin. Microbiol. 30:2826-2829
118. Wang, Y., S.A. Rollins, J.A. Madri, and L.A. Matis. 1995. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc. Natl. Acad. Sci. USA. 92:8955-8959. http://dx.doi.org/10.1073/pnas.92.19.8955
119. Wegner, N., K. Lundberg, A. Kinloch, B. Fisher, V. Malmström, M. Feldmann, and P.J. Venables. 2010. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol. Rev. 233:34-54. http://dx.doi.org/10.1111/j.0105-2896.2009.00850.x
120. Wen, W., D. Iwakiri, K. Yamamoto, S. Maruo, T. Kanda, and K. Takada. 2007. Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes. J. Virol. 81:1037-1042. http://dx.doi.org/10.1128/JVI.01416-06
121. Williams, R.C. Jr., and H.G. Kunkel. 1962. Rheumatoid factor, complement, and conglutinin aberrations in patients with subacute bacterial endocarditis. J. Clin. Invest. 41:666-675. http://dx.doi.org/10.1172/JCI104523
122. Winchester, R.J., V. Agnello, and H.G. Kunkel. 1970. Gamma globulin complexes in synovial fluids of patients with rheumatoid arthritis. Partial characterization and relationship to lowered complement levels. Clin. Exp. Immunol. 6:689-706
123. Woodruff, T.M., K.S. Nandakumar, and F. Tedesco. 2011. Inhibiting the C5-C5a receptor axis. Mol. Immunol. 48:1631-1642. http://dx.doi.org/10.1016/j.molimm.2011.04.014
124. Yamamoto, T., H. Nishiura, and H. Nishida. 1996. Molecular mechanisms to form leukocyte infiltration patterns distinct between synovial tissue and fluid of rheumatoid arthritis. Semin. Thromb. Hemost. 22:507-511. http://dx.doi.org/10.1055/s-2007-999052
125. Youinou, P., and G. Serre. 1995. The antiperinuclear factor and antikeratin antibody systems. Int. Arch. Allergy Immunol. 107:508-518. http://dx.doi.org/10.1159/000237093
126. Young, B.J., R.K. Mallya, R.D. Leslie, C.J. Clark, and T.J. Hamblin. 1979. Anti-keratin antibodies in rheumatoid arthritis. BMJ. 2:97-99. http://dx.doi.org/10.1136/bmj.2.6182.97
127. Zhou, Y., T. Di Pucchio, G.P. Sims, N. Mittereder, and T. Mustelin. 2015. Characterization of the hypercitrullination reaction in human neutrophils and other leukocytes. Mediators Inflamm. 2015:236451. http://dx.doi.org/10.1155/2015/236451
128. Zilberfarb, J.L., B.S. Andrews, A.C. Young, and J.S. Davis IV. 1985. Enhancement of Clq binding activity by IgM rheumatoid factor. J. Rheumatol. 12:444-448